Filtered By:
Specialty: Hematology
Nutrition: Vitamin K

This page shows you your search results in order of relevance. This is page number 4.

Order by Relevance | Date

Total 149 results found since Jan 2013.

Oral anticoagulant use in patients with morbid obesity: A systematic review and meta-analysis
CONCLUSIONS: Patients with morbid obesity on DOACs had similar risks of stroke/systemic embolism, lower rates of recurrent VTE and major bleeding events compared to those on VKAs. However, the certainty of evidence was low given that studies were mostly observational with high risk of confounding.PMID:34399433 | DOI:10.1055/a-1588-9155
Source: Thrombosis and Haemostasis - August 16, 2021 Category: Hematology Authors: Tzu-Fei Wang Marc Carrier Karine Fournier Deborah M Siegal Gr égoire Le Gal Aur élien Delluc Source Type: research

Oral anticoagulation patterns and prognosis in octogenarian patients with atrial fibrillation
In conclusion, in this cohort of post-discharge octogenarian patients with AF, the risk for all-cause death was similar in NOAC versus VKA users, after adjustment for baseline covariates. No differences in stroke and major bleeding events among these treatment groups were revealed.Graphic abstract
Source: Journal of Thrombosis and Thrombolysis - September 25, 2021 Category: Hematology Source Type: research

The Impact of Polypharmacy on the Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation
CONCLUSION: Polypharmacy was associated with increased thromboembolic, bleeding, and mortality risks in AF patients. NOACs had better benefit-risk profiles than VKAs in patients with polypharmacy.PMID:37369234 | DOI:10.1055/s-0043-1769735
Source: Thrombosis and Haemostasis - June 27, 2023 Category: Hematology Authors: Maxim Grymonprez Mirko Petrovic Tine L De Backer Stephane Steurbaut Lies Lahousse Source Type: research

Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-AF study.
CONCLUSION: If anything, despite its early termination the idrabiotaparinux regimen studied suggested a comparable efficacy to dose-adjusted warfarin, with a lower bleeding risk. This article is protected by copyright. All rights reserved. PMID: 24597472 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - March 5, 2014 Category: Hematology Authors: Buller HR, Halperin J, Hankey GJ, Pillion G, Prins MH, Raskob GE Tags: J Thromb Haemost Source Type: research

Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry.
In conclusion, in daily care, AF patients selected for VKA therapy are healthier than those treated with NOAC, demonstrate a high quality of anticoagulant control and very low stroke rates. However, the risk of major VKA bleeding is unacceptably high despite adequate patient selection and INR control and bleeding outcome is poor. PMID: 25994496 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - May 21, 2015 Category: Hematology Authors: Michalski F, Tittl L, Werth S, Hänsel U, Pannach S, Sahin K, Weiss N, Beyer-Westendorf J Tags: Thromb Haemost Source Type: research

Decision-making about the use of non-vitamin K oral anticoagulant therapies for patients with atrial fibrillation
Abstract Until recently, vitamin K antagonists, warfarin being the most commonly used agent in the United States, have been the only oral anticoagulant therapies available to prevent stroke in patients with atrial fibrillation (AF). In the last 5 years four new, non-vitamin K oral anticoagulants, the so-called NOACs or novel oral anticoagulants, have come to market and been approved by the Federal Drug Administration. Despite comparable if not superior efficacy in preventing AF-related stroke, and generally lower risks of major hemorrhage, particularly intracranial bleeding, the uptake of these agents has been s...
Source: Journal of Thrombosis and Thrombolysis - February 1, 2016 Category: Hematology Source Type: research

Dabigatran in real-world atrial fibrillation. Meta-analysis of observational comparison studies with vitamin K antagonists.
Abstract In the RE-LY clinical trial, dabigatran presented a better effectiveness/safety profile when compared to warfarin. However, clinical trials are not very representative of the real-world setting. We aimed to assess the performance of dabigatran in real-world patients with atrial fibrillation (AF) by means of a systematic review and meta-analysis of observational comparison studies with vitamin K antagonists (VKA). We searched PubMed, Embase and Scopus databases until November 2015 and selected studies according to the following criteria: observational study performed with nonvalvular AF patients; reporting...
Source: Thrombosis and Haemostasis - July 27, 2016 Category: Hematology Authors: Carmo J, Moscoso Costa F, Ferreira J, Mendes M Tags: Thromb Haemost Source Type: research

Anticoagulation prescribing patterns in patients with cancer
The objective of this retrospective cohort was to describe real-world anticoagulation prescribing patterns in cancer patients at a large academic medical center between January 1, 2013 and October 31, 2016. We sought to assess the safety, tolerability, and efficacy of DOACs in patients with cancer for either VTE and/or AF. Patient demographic, clinical characteristics, as well as bleeding and thrombotic events were collected. There were 214 patients in our analysis, of which 71 patients (33%) received a DOAC [apixaban (n  = 22), dabigatran (n = 17), and rivaroxaban (n = 32)]. There were fewer bleeding events an...
Source: Journal of Thrombosis and Thrombolysis - October 19, 2017 Category: Hematology Source Type: research

Use of Non –Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients with Malignancy: Clinical Practice Experience in a Single Institution and Literature Review
Semin Thromb Hemost DOI: 10.1055/s-0037-1607436This observational study aimed to investigate the efficacy and safety of non–vitamin K antagonist oral anticoagulants (NOACs) in atrial fibrillation (AF) patients with malignancy. A total of 76 patients (mean age: 73.2 ± 8.9; 28 females) with AF and malignancy treated with NOAC were included in the analysis. The mean CHA2DS2-VASc and HAS-BLED scores were 3.2 ± 1.2 and 2.2 ± 0.9, respectively. The study population was taking dabigatran 150 mg (25%) twice daily (BID), apixaban 5 mg BID (25%), dabigatran 110 mg BID (24%), rivaroxaban 20 mg (18%) once a da...
Source: Seminars in Thrombosis and Hemostasis - December 8, 2017 Category: Hematology Authors: Russo, Vincenzo Rago, Anna Papa, Andrea Antonio Meo, Federica Di Attena, Emilio Golino, Paolo D'Onofrio, Antonio Nigro, Gerardo Tags: Review Article Source Type: research

Effectiveness and Safety of Non-Vitamin K Oral Anticoagulants in Comparison to Phenprocoumon: Data from 61,000 Patients with Atrial Fibrillation.
Abstract All pivotal trials have evaluated non-vitamin K oral antagonists (NOACs) against warfarin. However, in some regions of the world, phenprocoumon is the most widely used vitamin K antagonist (VKA). There is little evidence documenting effectiveness and safety of NOACs compared with phenprocoumon in atrial fibrillation (AF). A retrospective cohort study using a German claims database was conducted to assess effectiveness (stroke, systemic embolism [SE]) and safety (bleeding leading to hospitalization) during therapy with NOACs and phenprocoumon in 61,205 AF patients. Hazard ratios (HRs) for effectiveness and...
Source: Thrombosis and Haemostasis - January 22, 2018 Category: Hematology Authors: Hohnloser SH, Basic E, Hohmann C, Nabauer M Tags: Thromb Haemost Source Type: research

Can an anticoagulant reduce brain hemorrhage: Invited comment on “Dabigatran reduces endothelial permeability through inhibition of thrombin-induced cytoskeleton reorganization”
During studies of anti-coagulants to prevent cardioembolic stroke, startling data emerged that patients treated with novel oral anti-coagulants (NOACs) appeared to suffer less brain hemorrhage than patients treated with traditional, vitamin-K depleting anticoagulants [1, 2]. That NOACs reduced the bleeding risk did not fit accepted dogma: clinicians imagine that hemorrhage occurs during and following ischemic stroke as the brain undergoes necrosis. In the presence of anti-coagulation, such necrotic bleeding ought to be augmented.
Source: Thrombosis Research - June 11, 2018 Category: Hematology Authors: Patrick D. Lyden Tags: Editorial Source Type: research

Anticoagulation in Atherosclerotic Disease.
Abstract The prevention of atherothrombotic events is an essential therapeutic goal in the treatment of patients with arteriosclerotic diseases. After plaque rupture, a rapidly growing thrombus can lead to acute vascular occlusion and thus heart attack, stroke or limb ischaemia. The acute therapy combines anticoagulation and platelet inhibition. However, the only available therapy so far in the primary and secondary prevention of stable patients is the platelet inhibitors aspirin and clopidogrel. Despite the use of antiplatelet therapies, including aspirin and P2Y12-receptor antagonists, some patients with artery ...
Source: Hamostaseologie - October 17, 2018 Category: Hematology Authors: Al Said S, Bode C, Duerschmied D Tags: Hamostaseologie Source Type: research

Thrombotic and Bleeding Outcomes Following Perioperative Interruption of Direct Oral Anticoagulants and Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation - a Comparative Analysis
Conclusions: The perioperative interruption of warfarin was associated with a higher 30-day rate of major bleeding as compared with DOAC interruption. Re-initiation of warfarin should be done judiciously following high bleeding risk procedures, and close INR monitoring may be warranted.DisclosuresShaw: Portola Pharmaceuticals: Research Funding. Douketis: Janssen: Consultancy; Pfizer: Other: Advisory Board; Boehringer-Ingelheim: Consultancy, Other: Advisory Board, Research Funding; Portola: Other: Advisory Board; The Medicines Company: Other: Advisory Board; Daiichi-Sankyo: Other: Advisory Board; Biotie: Other: Advisory Boa...
Source: Blood - November 21, 2018 Category: Hematology Authors: Shaw, J. R., Zhang, T., Le Gal, G., Douketis, J., Carrier, M. Tags: 332. Antithrombotic Therapy: Poster I Source Type: research

Efficacy and Safety of Prothrombin Complex Concentrate (PCC) for Direct Oral Anticoagulant Reversal: A Single Institutional Experience
ConclusionIn this cohort, 80% of pts demonstrated clinical stability/improvement of hemorrhage. All pts were able to undergo surgical procedures; however 17% required additional FFP to achieve hemostasis. Thromboembolism occurred in 12% of patients. No deaths could definitely be attributed to 4PCC; however, 30% of deaths could be attributable to the underlying hemorrhagic episode.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - November 21, 2018 Category: Hematology Authors: Sridharan, M., Ou, N. N., Oyen, L. J., Ashrani, A. A., McBane, R. D., Pruthi, R. K. Tags: 332. Antithrombotic Therapy: Poster II Source Type: research